Immutep Limited American Depositary Shares
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Open IMMP dashboard ↗Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Open KAPA dashboard ↗